Riskstratifiering vid pulmonell arteriell hypertension - Ger bättre behandling och prognos – högspecialiserat omhändertagande vid universitetssjukhusen krävs
Pulmonary arterial hypertension (PAH) is a progressive vascular disease, due to vasoconstriction and remodelling of pulmonary arteries. Survival has from diagnosis, if untreated, been found to be 1 to 2.8 years, depending on whether related to rheumatic disease or not. The ESC/ERS risk stratification tool provides a new approach to evaluate the clinical status of PAH patients. It supports a refine